Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock

Financing to be Used for the Development of a Portfolio of Treatments for Vascular Diseases and Ischemic Injuries Using Endonovo s Immunotronics Platform LOS ANGELES, CA ENDV, (Marketwired Nov 28, 2016) Endonovo Therapeutics, Inc. (OTCQB: ENDV) ( Endonovo or the Company ), a developer of non-invasive electroceuticals for the treatment of inflammatory conditions and diseases in vital organs, today announced that it has signed a term sheet with a single strategic healthcare investor for $5 million in Series B Preferred Stock financing
http://bit.ly/2gbWPVI